Just saw it. Nothing new of note to add. CEO reiterated the earlier point that reduced Rett clinic days in January were a major factor for lower revenue that month and there was a significant rebound in February and March back to the linear growth trajectory they were previously tracking on. No mention of any change to guidance or the like.
Other comments regarding the rest of the pipeline similar to previous commentary. Did note the recent trial failure for negative symptoms of schizophrenia was not because of no drug effect but more because placebo showed a higher change than expected so the drug failed to show a significant relative improvement.
Acadia, page-362
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.02 |
Change
0.080(0.62%) |
Mkt cap ! $1.664B | |||
| Open | High | Low | Value | Volume |
| $13.23 | $13.35 | $12.99 | $5.557M | 423.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1588 | $13.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.06 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |